MX2023003807A - Virus adenoasociados recombinantes para administracion en el snc o el musculo. - Google Patents

Virus adenoasociados recombinantes para administracion en el snc o el musculo.

Info

Publication number
MX2023003807A
MX2023003807A MX2023003807A MX2023003807A MX2023003807A MX 2023003807 A MX2023003807 A MX 2023003807A MX 2023003807 A MX2023003807 A MX 2023003807A MX 2023003807 A MX2023003807 A MX 2023003807A MX 2023003807 A MX2023003807 A MX 2023003807A
Authority
MX
Mexico
Prior art keywords
cns
associated viruses
recombinant adeno
muscle delivery
amino acid
Prior art date
Application number
MX2023003807A
Other languages
English (en)
Spanish (es)
Inventor
Ye Liu
Olivier Danos
Andrew Mercer
Samantha Yost
Subha Karumuthil-Melethil
Elad Firnberg
Joseph Bruder
Randolph Qian
April R Tepe
Jennifer M Egley
Original Assignee
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenxbio Inc filed Critical Regenxbio Inc
Priority claimed from PCT/US2021/054058 external-priority patent/WO2022076750A2/en
Publication of MX2023003807A publication Critical patent/MX2023003807A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2023003807A 2020-10-07 2021-10-07 Virus adenoasociados recombinantes para administracion en el snc o el musculo. MX2023003807A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088988P 2020-10-07 2020-10-07
PCT/US2021/054058 WO2022076750A2 (en) 2020-10-07 2021-10-07 Recombinant adeno-associated viruses for cns or muscle delivery

Publications (1)

Publication Number Publication Date
MX2023003807A true MX2023003807A (es) 2023-04-12

Family

ID=86184347

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003807A MX2023003807A (es) 2020-10-07 2021-10-07 Virus adenoasociados recombinantes para administracion en el snc o el musculo.

Country Status (9)

Country Link
US (1) US20230374541A1 (https=)
EP (1) EP4225778A2 (https=)
JP (1) JP2023545384A (https=)
KR (1) KR20230082613A (https=)
CN (1) CN116783209A (https=)
AU (1) AU2021358546A1 (https=)
CA (1) CA3193685A1 (https=)
IL (1) IL301563A (https=)
MX (1) MX2023003807A (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260055144A1 (en) * 2022-08-24 2026-02-26 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119330A2 (en) * 2016-12-22 2018-06-28 Oregon Health & Science University Adeno associated viral vectors
US11905312B2 (en) * 2017-02-15 2024-02-20 The University Of North Carolina At Chapel Hill Methods and compositions for gene transfer across the vasculature
WO2020160508A1 (en) * 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids

Also Published As

Publication number Publication date
EP4225778A2 (en) 2023-08-16
CA3193685A1 (en) 2022-04-14
AU2021358546A9 (en) 2024-02-08
US20230374541A1 (en) 2023-11-23
CN116783209A (zh) 2023-09-19
IL301563A (en) 2023-05-01
AU2021358546A1 (en) 2023-06-08
KR20230082613A (ko) 2023-06-08
JP2023545384A (ja) 2023-10-30

Similar Documents

Publication Publication Date Title
WO2022076750A3 (en) Recombinant adeno-associated viruses for cns or muscle delivery
SA519402565B1 (ar) F ناقل فرع حيوي لفيروس مرتبط بالغدة جديد واستخداماته
ZA202105975B (en) Variant aav capsids for intravitreal delivery
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
WO2019169004A8 (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
EA202091712A1 (ru) МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ
PH12020551938A1 (en) Liver targeting adeno-associated viral vectors
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
ZA202202242B (en) Isolated modified vp1 capsid protein of aav5
WO2022232327A3 (en) Aav capsids and uses thereof
MY190926A (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
MX2022013963A (es) Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
EP2561073A4 (en) VECTORS TO OBTAIN THE CENTRAL NERVOUS SYSTEM AND METHOD FOR THEIR USE
WO2012145509A3 (en) Adeno-associated-virus rep sequences, vectors, and viruses
WO2019222314A8 (en) Raav vectors encoding of lysosomal beta-galactosidase (glb1) and cathepsin a
MX2022002961A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
WO2020169755A3 (en) Antibodies
PH12022550109A1 (en) Modified aav capsid proteins for treatment of arthritic disease
PH12021552577A1 (en) Engineered producer cell lines and methods of making and using the same
MX2023006694A (es) Tratamiento de la enfermedad de danon.
MX2023003807A (es) Virus adenoasociados recombinantes para administracion en el snc o el musculo.
WO2023060272A3 (en) Recombinant adeno-associated viruses for cns tropic delivery
WO2022235614A3 (en) Novel aav vectors and methods and uses thereof
WO2024216244A3 (en) Targeting aav capsids, methods of manufacturing and using same
WO2024086352A3 (en) Compositions and methods for treating retinitis pigmentosa